Puma Biotechnology up 15% after quarterly earnings beats (NASDAQ:PBYI) | Seeking Alpha
Puma and CANBridge cancel licensing deal for $20m
Dennis Sanders - Senior Clinical Specialist - Puma Biotechnology, Inc. | LinkedIn
Puma Pharmaceutical Hotsell, SAVE 36% - kulturno.sk
Resumen: Puma Biotechnology y Pierre Fabre modifican el acuerdo de licencia de NERLYNX® para incluir la Gran China | Business Wire
Federal Jury Awards Puma Biotechnology Investors Damages in Securities Class-Action Verdict - Los Angeles Business Journal
Puma Biotechnology
Puma Biotechnology, Inc. (PBYI) Precio | Gráficos | Market Cap | Mercados | Exchanges, Calculadora de PBYI a USD | $3.16
Puma Biotechnology
Resumen: Puma Biotechnology y Pierre Fabre firman acuerdo de licencia exclusiva para desarrollar y comercializar NERLYNX® (neratinib) en Europa | Business Wire
Puma Pharmaceuticals Stock Shop, SAVE 30% - kulturno.sk
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Puma Biotechnology, Inc. | LinkedIn
El negocio bursátil de PUMA BIOTECHNOLOGY – Observatorio de biopolitica
Exhibitor Puma Biotechnology 11-6 - Scripps CME Connection
Puma Biotechnology
A New Drug on the Horizon for HER2 Breast Cancer Patients | Avise Analytics
Medical Affairs eLearning - MSL Society
Resumen: Puma Biotechnology y Pierre Fabre modifican el acuerdo de licencia de NERLYNX® para incluir la Gran China | Business Wire
PUMA BIOTECHNOLOGY, INC. : Precios y cotizaciones Acción | PBYI | US74587V1070 | MarketScreener
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | Fox Business
Pfizer Announces Agreement with Puma Biotechnology and Lyrica Success - Clinical Professionals
Puma Biotechnology, Inc. (PBYI) Company Information - Simply Wall St
Puma Pharmaceuticals Stock Shop, SAVE 30% - kulturno.sk
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Puma Biotechnology
